Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an independent educational grant from Amgen.
Philadelphia Marriott Downtown
Franklin Hall 8 - 10
1201 Market Street
Philadelphia, PA 19107
While statins have been the cornerstone of hypercholesterolemia treatment for over 30 years, a relatively large segment of this population remains at residual cardiovascular disease (CVD) risk, despite statin therapy. This may be due in part to statin intolerance or to the severity of cholesterol elevation, as seen in patients with familial hypercholesterolemia. With the availability of non-statin options, updated American College of Cardiology (ACC) Expert Consensus guidelines and National Lipid Association (NLA) recommendations now include PCSK9 inhibitors. Incorporating PCSK9 inhibitors and other non-statin therapies into clinical practice requires an understanding of new indications, guideline recommendations, and individualized patient strategies.
Please join us for Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know, a satellite symposium being held in Philadelphia in April 2019. This program is designed to help you apply the latest cholesterol-lowering national guidelines, and to assess the available evidence for non-statin options for patients who are not reaching lipid-lowering goals.
In this engaging, interactive, case-based symposium, a panel of renowned experts in dyslipidemia management will not only arm you with a knowledge of the latest clinical trial data on PCSK9 inhibitors, but they will also provide insights into the most challenging lipid-lowering scenarios for management of patients with CVD in your own practice. You will have the opportunity to question how the faculty members leverage existing clinical evidence to make decisions about selecting non-statin therapies for their patients, manage side effects, and adjust courses of treatment.
Benefits of Participating in This Engaging Program:
Expert interpretation of the latest national cholesterol-lowering guidelines
Guidance on issues of statin intolerance and severe hypercholesterolemia
Evidence-based strategies for management of dyslipidemia with non-statin therapies
Updates on indications for PCSK9 inhibitors and real-world experience to date
Network with your peers
This curriculum is directed toward all attendees of the 2019 ACP Meeting, including internists and internal medicine subspecialists. Nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment and management of patients with atherosclerosis may also attend and participate.
Upon successful completion of this activity, participants should have improved their ability to:
Interpret the latest guidelines and recommendations on cholesterol management from major clinical organizations
Determine when it is appropriate to use non-statin therapies
Please note that attendance is on a first-come, first-served basis. Please arrive early to ensure your spot!
For registration assistance, please email email@example.com, or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY 10022
You must be logged in to PER to register for this meeting